Full Text
PMS5 Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-to-Severe Rheumatoid Arthritis

Abstract

Authors

K.A. Hicks S.R. Earnshaw J.W. Shaw M. Cifaldi

Back to Volume 15, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×